Skip to content
Trial Eligibility
Menu

MASH / NASH (Fatty Liver Disease) Clinical Trials near Miami, FL

20 studies for MASH / NASH (Fatty Liver Disease) are recruiting at 105 sites within 50 miles of Miami, Florida, according to ClinicalTrials.gov data processed .

Distances are city-level approximations. See all MASH / NASH (Fatty Liver Disease) trials in the US or all trials near Miami.

Your ZIP is looked up in your browser. We don't receive or store it.

Recruiting now

MASH / NASH (Fatty Liver Disease) studies enrolling near Miami

Showing 20 studies, nearest first.
  1. LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

    NCT06632457

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: BioMed Research & Medical Center (Miami, FL); ECIR Miami Holdings LLC dba IMIC (Miami, FL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    16 sites within 50 mi
  2. LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

    NCT06632444

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: BioMed Research & Medical Center (Miami, FL); ECIR Miami Holdings LLC dba IMIC (Miami, FL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    15 sites within 50 mi
  3. A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

    NCT07221227

    • Phase 3
    • Ages 18 to 75 years
    • Sex: All

    Nearest sites: GSK Investigational Site (Miami, FL); GSK Investigational Site (Miami, FL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    12 sites within 50 mi
  4. A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

    NCT07221188

    • Phase 3
    • Ages 18 to 75 years
    • Sex: All

    Nearest sites: GSK Investigational Site (Miami, FL); GSK Investigational Site (Miami, FL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    11 sites within 50 mi
  5. A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

    NCT06215716

    • Phase 3
    • Ages 18 to 80 years
    • Sex: All

    Nearest sites: Akero Clinical Study Site (Miami, FL); Akero Clinical Study Site (Miami, FL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    9 sites within 50 mi
  6. A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

    NCT06528314

    • Phase 3
    • Ages 18 to 80 years
    • Sex: All

    Nearest sites: Akero Clinical Study Site (Miami, FL); Akero Clinical Study Site (Miami, FL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    9 sites within 50 mi
  7. A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

    NCT07165028

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Evolution Clinical Trials (Miami, FL); AMR Clinical (Doral, FL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    7 sites within 50 mi
  8. A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

    NCT06419374

    • Phase 3
    • Ages 18 to 75 years
    • Sex: All

    Nearest sites: 89bio Clinical Study Site (Miami, FL); 89bio Clinical Study Site (Miami, FL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    6 sites within 50 mi
  9. A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition

    NCT05519475

    • Phase 2
    • Ages 18 to 75 years
    • Sex: All

    Nearest sites: Genoma Research Group, Inc. (Miami, FL); Med Research of Florida, LLC (Miami, FL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  10. A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

    NCT06318169

    • Phase 3
    • Ages 18 to 80 years
    • Sex: All

    Nearest sites: 89bio Clinical Study Site (Miami, FL); 89bio Clinical Study Site (Hialeah Gardens, FL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  11. A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

    NCT05648214

    • Phase 1/2
    • Ages 18 to 75 years
    • Sex: All
    • Accepts healthy volunteers

    Nearest sites: Genoma Research Group, Inc (Miami, FL); Med Research of Florida, LLC (Miami, FL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  12. A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)

    NCT07288138

    • Phase 2
    • Ages 18 to 75 years
    • Sex: All

    Nearest sites: Evolution Clinical Trials (Miami, FL); Floridian Clinical Research, LLC (Miami Lakes, FL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  13. A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

    NCT07701993

    • Phase 3
    • Ages 18 to 75 years
    • Sex: All

    Nearest sites: GSK Investigational Site (Miami, FL); GSK Investigational Site (Miami, FL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  14. A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

    NCT07704892

    • Phase 3
    • Ages 18 to 75 years
    • Sex: All

    Nearest sites: GSK Investigational Site (Miami, FL); GSK Investigational Site (Miami, FL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  15. Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States

    NCT05832229

    • Phase 2
    • Ages 18 to 75 years
    • Sex: All

    Nearest site: University of Miami Health System (Miami, FL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  16. A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH

    NCT06920043

    • Phase 2
    • Ages 18 to 75 years
    • Sex: All

    Nearest site: GSK Investigational Site (Miami, FL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  17. Evaluation of Non-Invasive Tests for Metabolic Liver Disease

    NCT07122700

    • Observational
    • Ages 18 to 75 years
    • Sex: All

    Nearest site: Clinical Pharmacology of Miami (Miami, FL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  18. Phase 1/2 Study of OPK-88006 in Healthy and Presumed MASH Participants

    NCT07512427

    • Phase 1/2
    • Ages 18 to 75 years
    • Sex: All
    • Accepts healthy volunteers

    Nearest site: OPKO study site (Miami, FL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  19. A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD

    NCT07527910

    • Phase 2
    • Ages 18 to 75 years
    • Sex: All

    Nearest site: Evolution Clinical Trials (Miami, FL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  20. Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH

    NCT07795164

    • Phase 3
    • Ages 18 to 75 years
    • Sex: All

    Nearest site: Altimmune Clinical Study Site (Miami, FL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi

FAQ

Common questions

What is a clinical trial?
A clinical trial is a research study in people that tests a medical, surgical or behavioral intervention, such as an investigational drug or device. Observational studies are also listed: they collect information without assigning a treatment. Read how clinical trials work.
Is there compensation for joining a MASH / NASH (Fatty Liver Disease) clinical trial?
Compensation for time and travel may be available, but it varies by study and some studies offer none. The amount and schedule are reviewed by an ethics board and described in the consent form. See compensation in clinical trials.
How do I check if I'm eligible?
Each study lists age, sex and other inclusion and exclusion criteria on its ClinicalTrials.gov record. Only the study team can confirm eligibility, usually through a screening call or visit. Talk with your own doctor before joining any study.

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.